Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 10:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 52 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Eplerenone Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

The Role of Minerelocorticoid Receptor on Modulating Aldosterone Production

NCT02871648
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Placebo, Fludrocortisone, Eplerenone
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 40 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Sep 13, 2026, 10:59 AM EDT
Recruiting Phase 4 Interventional

Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study

NCT05030545
View directory record Official record
Conditions
Primary Aldosteronism, Hypertension
Interventions
Eplerenone
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Sep 13, 2026, 10:59 AM EDT
Completed Early Phase 1 Interventional Results available

Pressure Assessment to Improve Outcomes After TAVR: a Registry

NCT03923530
View directory record Official record
Conditions
Hypertension, Aortic Stenosis, Calcific, Quality of Life, Heart Failure With Preserved Ejection Fraction
Interventions
Eplerenone
Drug
Lead sponsor
North Florida Foundation for Research and Education
Other
Eligibility
55 Years to 100 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Sep 13, 2026, 10:59 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Eplerenone in the Treatment of Hypertension in Children.

NCT00147589
View directory record Official record
Conditions
Hypertension
Interventions
Eplerenone
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
6 Years to 16 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
28
States / cities
Little Rock, Arkansas • Beverly Hills, California • Inglewood, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Sep 13, 2026, 10:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Hypoglycemia and the Mineralocorticoid Receptor

NCT01394627
View directory record Official record
Conditions
Hypoglycemia
Interventions
Eplerenone, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 40 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Sep 13, 2026, 10:59 AM EDT
Withdrawn Phase 4 Interventional

Eplerenone as a Supplement to Epidural Steroid Injections

NCT03418649
View directory record Official record
Conditions
Degenerative Intervertebral Discs, Sciatic Radiculopathy, Low Back Pain
Interventions
Eplerenone 50 Mg Tab, Placebo Oral Tablet
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Cincinnati, Ohio • West Chester, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Sep 13, 2026, 10:59 AM EDT
Completed Phase 4 Interventional Results available

EWISE: Study of Eplerenone in Women With Chest Pain, Coronary Vascular Dysfunction and Evidence of Myocardial Ischemia

NCT00187889
View directory record Official record
Conditions
Ischemic Heart Disease
Interventions
Eplerenone, Placebo or sugar pill
Drug
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 75 Years · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 13, 2013 · Synced Sep 13, 2026, 10:59 AM EDT
Withdrawn Phase 4 Interventional

CLCNKA (Ka Renal Chloride Channel[ClC-Ka]) Polymorphism Effects on Hypertrophy Regression

NCT01275352
View directory record Official record
Conditions
Hypertension
Interventions
Eplerenone, placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
40 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
St Louis, Missouri • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Sep 13, 2026, 10:59 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Treatment of Post-Ocriplasmin Therapy Vitreolysis Induced Subretinal Fluid With Eplerenone (Mineralocorticoid Antagonists)

NCT04300881
View directory record Official record
Conditions
Vitreomacular Traction, Subretinal Edema
Interventions
Eplerenone
Drug
Lead sponsor
Wagner Macula & Retina Center
Other
Eligibility
19 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Sep 13, 2026, 10:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects Of Eplerenone On Serum Aldesterone And Plasma Renin Activity

NCT00990223
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Eplerenone or Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
2
States / cities
Miami, Florida • South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Sep 13, 2026, 10:59 AM EDT
Completed Not applicable Interventional Results available

Eplerenone in HIV Associated Abdominal Fat Accumulation

NCT01405456
View directory record Official record
Conditions
HIV
Interventions
Eplerenone and lifestyle, placebo and lifestyle
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
30 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Sep 13, 2026, 10:59 AM EDT
Terminated Phase 4 Interventional Results available

The Effects of Eplerenone on Markers of Myocardial Fibrosis in Adult Congenital Heart Disease

NCT01971593
View directory record Official record
Conditions
Tetralogy of Fallot, Transposition of the Great Vessels With an Arterial Switch, Single Ventricle With a Fontan Palliation
Interventions
Eplerenone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 3, 2018 · Synced Sep 13, 2026, 10:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Eplerenone on Postprandial Inflammatory Response in Healthy Adults

NCT01786551
View directory record Official record
Conditions
Systemic Proinflammatory State
Interventions
Eplerenone
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Sep 13, 2026, 10:59 AM EDT
Terminated Phase 4 Interventional

Reversing Endothelial and Diastolic Dysfunction and Improving Collagen Turnover in Diastolic Heart Failure

NCT00293150
View directory record Official record
Conditions
Diastolic Heart Failure
Interventions
Eplerenone
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Sep 13, 2026, 10:59 AM EDT
Recruiting Phase 4 Interventional

Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension

NCT05593055
View directory record Official record
Conditions
Hypertension, Left Ventricular Hypertrophy
Interventions
Eplerenone, Chlorthalidone, Potassium
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 13, 2026, 10:59 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

MR and Inflammation After Preeclampsia

NCT07345845
View directory record Official record
Conditions
Preeclampsia, Preeclampsia Postpartum
Interventions
Eplerenone
Drug
Lead sponsor
Anna Stanhewicz, PhD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Sep 13, 2026, 10:59 AM EDT
Completed Phase 4 Interventional Results available

Endogenous Renin-Angiotensin-Aldosterone System and Glucose Metabolism

NCT02034435
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Low Salt diet plus Placebo tablet, Low Sodium diet plus Salt tablet, Epleronone, Amlodipine
Other · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Sep 13, 2026, 10:59 AM EDT
Terminated Phase 2 Interventional Results available

Cardiometabolic Effects of Eplerenone in HIV Infection

NCT02629094
View directory record Official record
Conditions
Cardiac Steatosis, Hepatic Steatosis
Interventions
Inspra /Eplerenone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Sep 13, 2026, 10:59 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Eplerenone and IOP in Healthy Adults

NCT07795762
View directory record Official record
Conditions
Intraocular Pressure (IOP), Healthy Adult
Interventions
Eplerenone, Microcrystalline Cellulose NF (placebo)
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 13, 2026, 10:59 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Defining Strategies for Improving Endothelial and Fibrinolytic Dysfunction in Obesity

NCT00608465
View directory record Official record
Conditions
Metabolic Syndrome X
Interventions
Eplerenone, Ramipril
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Sep 13, 2026, 10:59 AM EDT
Completed Phase 2 Interventional Results available

Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone

NCT01807221
View directory record Official record
Conditions
Heart Failure
Interventions
Finerenone (BAY94-8862), Placebo, Inspra (eplerenone)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,066 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
10
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2021 · Synced Sep 13, 2026, 10:59 AM EDT
Completed Phase 3 Interventional Results available

Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy

NCT02354352
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Eplerenone, Spironolactone
Drug
Lead sponsor
Ohio State University
Other
Eligibility
7 Years and older · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • Kansas City, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2019 · Synced Sep 13, 2026, 10:59 AM EDT
Completed No phase listed Observational

Glucose Metabolism in Subjects With Aldosterone-Producing Adenomas

NCT02362308
View directory record Official record
Conditions
Primary Aldosteronism
Interventions
Adrenalectomy, mineralocorticoid receptor antagonist
Other · Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Sep 13, 2026, 10:59 AM EDT
Completed Phase 2 Interventional Results available

Eplerenone for Central Serous Chorioretinopathy

NCT01822561
View directory record Official record
Conditions
Central Serous Chorioretinopathy
Interventions
Eplerenone 50mg
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Sep 13, 2026, 10:59 AM EDT